Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients

Evaluation of Irisin as a Novel Diagnostic Marker for Early Detection and Progression of Diabetic Nephrophathy

Study the relation between irisin level and progression of diabetic nephropathy and its early detection.

Diabetes is a prevalent worldwide challenge affecting 425 million individuals, with the International Diabetes Federation (IDF) projecting a rise to 630 million by 2045. Diabetic nephropathy (DN) is a critical complication that impacts one-third of diabetic patients and significantly contributes to cardiovascular morbidity and mortality, leading to substantial socioeconomic burdens (Dwivedi and Sikarwar, 2024).

Diabetic nephropathy (DN) is a multifaceted condition involving various interconnected mechanisms, primarily influenced by hyperglycemia .

Diabetic nephropathy (DN) is one of the most feared diabetic chronic microvascular complications and the major cause of end-stage renal disease (ESRD).

Therefore, early recognition is crucial. Presently, this relies on the albumin excretion rate (AER) and glomerular filtration rate (GFR).

Irisin, an exercise - induced myokine, has been linked to metabolic disorders, but its relationship with DN remains unclear.

Experimental studies have demonstrated the role of irisin in protecting mice against diabetes and obesity

Inclusion Criteria:

Type 2 diabetic patients

Exclusion Criteria:

• Non-diabetic kidney diseases.
• Acute illness, infection, obesity, hypertension, type 1 DM.
• Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.